View Document Preview and Link Open Document File Size: 828,59 KB Share Result on Facebook
City Rochester / IDEC / Frankfurt / / Company Libertas Academica Ltd. / IgG / North American Intergroup / Parikh SA / Cox / National Cancer Institute-Working Group / US Intergroup / / Country United States / / Currency pence / USD / / / Event FDA Phase / Judicial Event / / IndustryTerm treatment for patients with chronic lymphocytic leukemia / treatment of non-Hodgkin’s lymphoma / Treatment of relapsed chronic lymphocytic leukemia / Treatment of fludarabine-refractory chronic lymphocytic leukemia / Treatment of Relapsed and Refractory Disease / treatment of patients with chronic lymphocytic leukemia / therapy for previously untreated chronic lymphocytic leukemia / therapy for relapsed indolent lymphoma / therapy for chronic lymphocytic leukemia / scientific publication machinery / therapy of younger patients with chronic lymphocytic leukemia / diagnostic tools / treatment of high-risk chronic lymphocytic leukemia / Treatment of Chronic Lymphocytic Leukemia / therapy of chronic lymphocytic leukemia / therapeutics for relapsed/refractory disease / / MedicalCondition refractory disease / lymphocytic leukemia / lymphoma / relapsed chronic lymphocytic leukemia / herpes zoster / chronic lymphocytic leukemia / infectious complications / follicular lymphoma / bulky lymphadenopathy / serious infections / hepatitis B / double refractory disease / relapsed/refractory disease / leukaemia / Ferrarini M. Chronic lymphocytic leukemia / immune thrombocytopenic purpura / Kay Introduction Chronic / transient neutropenia / Progressive multifocal leukoencephalopathy / lymphadenopathy / bulky nodal disease / low-grade lymphoma / nonHodgkin lymphomas / prior resolved hepatitis B / hepatitis / non-Hodgkin’s lymphoma / chronic lymphocytic leukemia / MS / renal dysfunction / et al. Hepatitis B / Relapsed/Refractory Chronic Lymphocytic Leukemia / previously untreated chronic lymphocytic leukemia / refractory chronic lymphocytic leukemia / patient and fatal interstitial lung disease / Leukemia / Chronic Lymphocytic Leukemia Chadi Nabhan1 / Leuk Lymphoma / Cancer / disease / high-risk chronic lymphocytic leukemia / fludarabine-refractory chronic lymphocytic leukemia / shortness of breath / chills / high disease / Relapsed/Refractory CD20+ Malignant Disease / relapsed and refractory chronic lymphocytic leukemia / F refractory and bulky disease / infectious complications risks / lymphocytosis / B-cell chronic lymphocytic leukemia / Cytokine-release syndrome / urticaria / refractory follicular lymphoma / chronic lymphocytic leukaemia / infection / relapsed indolent lymphoma / relapsed disease / rash / B-cell lymphoma / B chronic lymphocytic leukemia / small lymphocytic lymphoma / / MedicalTreatment salvage therapy / combination chemotherapy / anticancer therapy / chemotherapy / immunotherapy / chemotherapies / combination chemotherapies / antibody therapy / / Organization National Cancer Institute / Division of Hematology/Oncology / Lutheran General Hospital / American Society of Clinical Oncology / Department of Medicine / OR CR RD / FDA / / Person Treatment / Bleeker / Nabhan Ofatumumab Ofatumumab / Nabhan / Kay Ofatumumab Ofatumumab (Ofa) / Plus Rituximab / Humanized Responses / / Position scientist / Advocate / author / mouse xenograft model / / Product cladribine / cyclophosphamide / pentostatin / Campath / beta-2 / this / German CLL / relapsed/refractory CLL / E2997 / rituximab / CD20 / Minnie Pearl Cancer / Ofa / RO5072759 / / ProgrammingLanguage R / / ProvinceOrState Minnesota / Illinois / Oregon / South Carolina / / RadioStation Tsimberidou AM / Evens AM / / Technology antibodies / transplantation / stem cells / apoptosis / pharmacokinetics / chemotherapy / / URL http / SocialTag 
Microsoft Word - urm-January_26_2011-OFA_2011_r~CN_NK.doc